Celcuity Inc (CELC)

$17.54

+0.3

(+1.74%)

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Celcuity Inc

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 231.4% return, outperforming this stock by 263.3%

Performance

  • $16.98
    $17.67
    $17.54
    downward going graph

    3.19%

    Downside

    Day's Volatility :3.9%

    Upside

    0.74%

    downward going graph
  • $8.39
    $22.19
    $17.54
    downward going graph

    52.17%

    Downside

    52 Weeks Volatility :62.19%

    Upside

    20.96%

    downward going graph

Returns

PeriodCelcuity IncSector (Health Care)Index (Russel 2000)
3 Months
15.09%
-0.7%
0.0%
6 Months
75.22%
9.2%
0.0%
1 Year
82.52%
3.5%
-1.3%
3 Years
-30.73%
12.3%
-22.1%

Highlights

Market Capitalization
534.1M
Book Value
$5.48
Earnings Per Share (EPS)
-2.69
Wall Street Target Price
28.6
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-22.56%
Return On Equity TTM
-46.63%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-66.1M
Diluted Eps TTM
-2.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.92
EPS Estimate Next Year
-3.39
EPS Estimate Current Quarter
-0.73
EPS Estimate Next Quarter
-0.77

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Celcuity Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 63.06%

Current $17.54
Target $28.60

Technicals Summary

Sell

Neutral

Buy

Celcuity Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Celcuity Inc
Celcuity Inc
-1.46%
75.22%
82.52%
-30.73%
-17.46%
Moderna, Inc.
Moderna, Inc.
-3.81%
28.95%
-26.59%
-39.67%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.28%
12.73%
12.52%
82.86%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-4.7%
26.35%
43.96%
230.98%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.87%
7.24%
20.15%
82.55%
128.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Celcuity Inc
Celcuity Inc
NA
NA
NA
-2.92
-0.47
-0.23
NA
5.48
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Celcuity Inc
Celcuity Inc
Buy
$534.1M
-17.46%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
128.04%
28.33
36.68%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    7.21%
  • Soleus Capital Management, L.P.

    7.16%
  • VR Adviser, LLC

    6.91%
  • COMMODORE CAPITAL LP

    5.76%
  • Perceptive Advisors LLC

    4.86%
  • NEA Management Company, LLC

    4.10%

Corporate Announcements

  • Celcuity Inc Earnings

    Celcuity Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.

Organization
Celcuity Inc
Employees
55
CEO
Mr. Brian F. Sullivan
Industry
Commercial Services

FAQs